Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe clinical trial record for the PROCEED study is displayed, describing its pembrolizumab and chemoradiation treatment plan, participant criteria, measured outcomes, and completed status.SummaryDifference44%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH announcement banner was added with links to transition updates and a notice about the agency’s shift from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating restricted access to the study record. As a result, only basic site chrome is visible while the main study details are inaccessible.SummaryDifference18%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.